Researchers at the University of California, Irvine have identified a specific polyunsaturated fatty acid that reversed age-related vision decline in older mice, offering a potential pathway to treat human retinal aging.
The treatment works by replenishing very-long-chain polyunsaturated fatty acids in the retina
As the eye ages, lipid metabolism changes reduce levels of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) in the retina, which are essential for maintaining visual function and whose decline increases the risk of age-related macular degeneration. The study builds on prior research showing that the ELOVL2 gene, a marker of aging, drives production of these fatty acids and docosahexaenoic acid (DHA), but that boosting ELOVL2 activity alone improved vision in mice by raising retinal DHA levels.
Scientists bypassed the ELOVL2 enzyme by direct fatty acid supplementation
To avoid relying on the ELOVL2 enzyme, which may be less active in aged tissues, researchers injected older mice with a specific polyunsaturated fatty acid not identified by name in the source material. This intervention improved visual performance in the animals, whereas supplementation with DHA alone did not produce the same effect, confirming that DHA cannot independently reverse vision loss in this model.
The findings suggest a new direction for preventing age-related eye disease
By demonstrating that direct supplementation with certain polyunsaturated fatty acids can restore vision in aged mice without requiring ELOVL2 activity, the study provides proof-of-concept for a lipid-based therapy targeting retinal aging. The approach could eventually inform strategies to slow or prevent age-related macular degeneration, a leading cause of vision loss in older adults, though the source does not indicate timelines for human trials or clinical translation.
What fatty acid was used in the treatment?
The source does not specify the exact polyunsaturated fatty acid injected into the mice, only that it was not DHA and that it improved visual performance in aged animals.
Could this therapy work in humans?
The study was conducted in mice, and the source provides no evidence or timeline for whether the fatty acid supplementation would restore vision in human eyes or prevent age-related macular degeneration in people.
